Goldman Sachs reiterates Buy on Gossamer Bio stock despite dip after deal news

Goldman Sachs has reiterated its Buy rating and an $8 price target for Gossamer Bio (GOSS), despite a recent stock drop and InvestingPro's assessment of overvaluation, following the company's announcement of an option agreement to acquire privately-held Respira Therapeutics. This strategic move aims to integrate Respira's 'clinically derisked' RT234, an inhaled pulmonary hypertension therapy, into Gossamer's pipeline, with the deal involving upfront share issuance and potential future milestones. While other analysts also maintain bullish ratings and anticipate the PROSERA trial readout in February 2026, the company continues to face challenges with rapid cash burn and negative earnings.

Analysis

Gossamer Bio (NASDAQ:GOSS) has executed a strategic option agreement to potentially acquire Respira Therapeutics, a move that provides access to RT234, an inhaled therapy for pulmonary hypertension. Despite this development, GOSS stock fell 7.0%, underperforming the XBI index, which declined 1.6%. This near-term negative reaction contrasts with the stock's more than 200% surge year-to-date. Analyst sentiment remains decidedly bullish; Goldman Sachs reiterated its 'Buy' rating and $8.00 price target, viewing RT234 as 'clinically derisked' due to its active ingredient, vardenafil, already being an approved drug. This sentiment is echoed by H.C. Wainwright ($10 PT) and Cantor Fitzgerald, with consensus targets ranging from $6 to $15. However, this optimism is tempered by significant fundamental headwinds identified by InvestingPro, including a rapid cash burn, negative earnings, and a current assessment that the stock is 'overvalued'. The deal structure itself introduces dilution, with 2.5 million shares issued upfront and another 1.5 million upon option exercise. Investors are now focused on upcoming catalysts, including further clarity on RT234's trial design and market differentiation, as well as the PROSERA clinical trial readout scheduled for February 2026.

Key Decisions for Investors

• Investors should view GOSS as a speculative, catalyst-driven holding, balancing the significant upside potential implied by analyst price targets ($6-$15) against fundamental weaknesses like rapid cash burn and negative earnings.
• Closely monitor for forthcoming data or management commentary on RT234's clinical trial design and market differentiation, as this will be critical to validating the strategic rationale behind the Respira acquisition.
• Factor in the dilutive impact of the share issuance for the Respira option while positioning for the next major potential inflection point, the PROSERA clinical trial readout in February 2026.
• Given the conflicting signals of strong analyst ratings versus an 'overvalued' assessment and poor fundamentals, consider the stock's high volatility and size positions according to risk tolerance.